Lactoferrin COVID-19 studies.
Recent:Andreu Yazawa Matino.
Lactoferrin has been officially adopted
in 1 country.
Submit updates/corrections .
Jun 3 |
(Preprint) (meta analysis) | Lactoferrin for COVID-19: real-time meta analysis of 6 studies |
| Statistically significant improvement is seen for viral clearance. 2 studies from 2 independent teams (both from the same country) show statistically significant improvements in isolation (1 for the most serious outcome). • Meta analysi.. | ||
Apr 15 |
et al., Viruses, doi:10.3390/v15040972 (In Vitro) | Liposomal Lactoferrin Exerts Antiviral Activity against HCoV-229E and SARS-CoV-2 Pseudoviruses In Vitro |
| In Vitro study showing more potent antiviral activity for SARS-CoV-2 and HCoV229E with liposomal lactoferrin compared with free lactoferrin. Authors note that liposomal encapsulation has been shown to increase permeability, bioavailabilit.. | ||
Mar 31 |
et al., Research Square, doi:10.21203/rs.3.rs-2676422/v1 (Preprint) (In Vitro) | Evaluation of SARS-CoV-2 isolation in cell culture from nasal/nasopharyngeal swabs or saliva specimens of patients with COVID-19 |
| Analysis of nasal/nasopharyngeal swabs and saliva specimens, showing significantly lower isolation efficiency of SARS-CoV-2 in saliva specimens. In Vitro study showing that lactoferrin and amylase, components of saliva, were found to inhi.. | ||
Mar 4 |
et al., Nutrients, doi:10.3390/nu15051285 | Effect of Lactoferrin on Clinical Outcomes of Hospitalized Patients with COVID-19: The LAC Randomized Clinical Trial |
| 12% higher mortality [p=0.85], 45% higher ventilation [p=0.39], 6% higher combined mortality/ICU admission [p=0.87], and 34% worse recovery [p=0.12]. RCT 218 hospitalized patients in Italy, showing no significant differences with lactoferrin treatment. Authors note that in several previous studies showing clinical improvement, lactoferrin was given at an earlier stage of disease. Autho.. | ||
Dec 7 |
et al., BioMetals, doi:10.1007/s10534-022-00477-3 | Bovine lactoferrin for the prevention of COVID-19 infection in health care personnel: a double-blinded randomized clinical trial (LF-COVID) |
| 59% more symptomatic cases [p=0.34] and 23% more cases [p=0.65]. Early terminated low-risk patient prophylaxis RCT in Peru, showing no significant difference in cases with lactoferrin. There were no moderate or severe cases. | ||
Aug 3 |
et al., BioMetals, doi:10.1007/s10534-022-00427-z (Review) | An overview on in vitro and in vivo antiviral activity of lactoferrin: its efficacy against SARS-CoV-2 infection |
| Review of the antiviral activity of lactoferrin and efficacy for SARS-CoV-2. | ||
May 17 |
et al., Research Square, doi:10.21203/rs.3.rs-1605740/v1 (Preprint) (In Vitro) | Lactoferrin binding to Sars-CoV-2 Spike glycoprotein protects host from infection, inflammation and iron dysregulation. |
| Vero E6, Caco-2, and THP-1 In Vitro study showing lactoferrin inhibited SARS-CoV-2 spike pseudovirus. Nutraceutically available bovine lactoferrin was more effective than human lactoferrin. | ||
May 13 |
et al., International Journal of Molecular Sciences, doi:10.3390/ijms23105436 (In Vitro) | Lactoferrin Inhibition of the Complex Formation between ACE2 Receptor and SARS CoV-2 Recognition Binding Domain |
| Biolayer interferometry and turbidimetry study showing lactoferrin inhibits ACE2 - SARS-CoV-2 RBD binding. | ||
Nov 20 2021 |
et al., Pathogens, doi:10.3390/pathogens10111514 (In Vitro) | Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells |
| Vero E6 and H23 In Vitro study finding SARS-CoV-2 antiviral activity associated with agonism of the sigma-1 receptor, ligation of the sigma-2 receptor, and a combination of the two. Authors identify synergistic effects with the combinatio.. | ||
Oct 28 2021 |
et al., World Journal of Gastroenterology, doi:10.3748/wjg.v27.i40.6951 | Hepatic and gastrointestinal disturbances in Egyptian patients infected with coronavirus disease 2019: A multicentre cohort study |
| 79% lower mortality [p=0.11]. Retrospective 547 hospitalized COVID+ patients in Egypt, showing lower mortality with lactoferrin treatment (without statistical significance). | ||
Oct 19 2021 |
et al., International Journal of Environmental Research and Public Health, doi:10.3390/ijerph182010985 | Lactoferrin as Antiviral Treatment in COVID-19 Management: Preliminary Evidence |
| 47% faster viral clearance [p=0.0001]. Small prospective study in Italy with 32 lactoferrin patients, 32 SOC, and 28 patients with no treatment, showing significantly faster viral clearance and improved recovery with treatment. Oral and intranasal lactoferrin. | ||
Sep 21 2021 |
et al., Journal of Clinical Medicine, doi:10.3390/jcm10184276 | Ambulatory COVID-19 Patients Treated with Lactoferrin as a Supplementary Antiviral Agent: A Preliminary Study |
| 76% lower hospitalization [p=0.32], 40% slower recovery [p=0.5], and 39% faster viral clearance [p=0.02]. Retrospective survey based study in Italy with 82 patients treated with lactoferrin, and 39 control patients, showing significantly faster viral clearance with treatment. There was no significant difference in recovery time overall, howev.. | ||
Sep 3 2021 |
et al., Clinical Nutrition ESPEN, doi:10.1016/j.clnesp.2021.08.019 | Lactoferrin reduces the risk of respiratory tract infections: A meta-analysis of randomized controlled trials |
| Meta analysis of 6 RCTs, showing lower risk of respiratory tract infections with lactoferrin. | ||
Aug 19 2021 |
et al., Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2105815118 (In Vitro) | Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19 |
| In Vitro study testing 1,425 compounds for SARS-CoV-2 antiviral activity, identifying 17 dose-responsive compounds with IC50 values <1μM. Lactoferrin inhibited SARS-CoV-2 in the nanomolar range in all cell models with multiple modes of ac.. | ||
Aug 19 2021 |
et al., Medicina, doi:10.3390/medicina57080842 | The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study |
| 25% improved recovery [p=1]. RCT 54 hospitalized patients in Egypt, showing no significant differences in recovery with lactoferrin treatment. 200mg lactoferrin orally once daily (group 1) or 200mg lactoferrin orally twice daily (group 2). | ||
Apr 14 2021 |
et al., PeerJ, doi:10.7717/peerj.11303 (Review) | Natural resources to control COVID-19: could lactoferrin amend SARS-CoV-2 infectivity? |
| Review of the mechanisms of action and evidence for beneficial effects of lactoferrin for COVID-19. | ||
Feb 15 2021 |
et al., Frontiers in Molecular Biosciences, doi:10.3389/fmolb.2021.607443 | Molecular Mechanisms Behind Anti SARS-CoV-2 Action of Lactoferrin |
| In Silico study of possible molecular mechanisms for anti-SARS-CoV-2 action of lactoferrin. | ||
Jan 23 2021 |
et al., Nutrients, doi:10.3390/nu13020328 (In Vitro) | Protective Effects of Lactoferrin against SARS-CoV-2 Infection In Vitro |
| Caco-2 and Vero E6 In Vitro study showing lactoferrin enhances the antiviral immune response, partially inhibits SARS-CoV-2 infection in Caco-2 intestinal epithelial cells, and modulates cytokine production. | ||
Sep 30 2020 |
et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106118 (Review) | Lactoferrin as potential preventative and adjunct treatment for COVID-19 |
| Review of the antiviral, anti-inflammatory, and immunomodulatory effects of lactoferrin and the potential benefit for COVID-19. | ||
Jul 11 2020 |
et al., International Journal of Molecular Sciences, doi:10.3390/ijms21144903 (Review) | Lactoferrin as Protective Natural Barrier of Respiratory and Intestinal Mucosa against Coronavirus Infection and Inflammation |
| Review of the mechanisms of action and potential benefits of lactoferrin for COVID-19. Authors propose designing a trial combining an intranasal spray and oral administration (which they later performed). | ||
Apr 1 2020 |
et al., International Journal of Research in Health Sciences, doi:10.5530/ijrhs.8.1.3 | Liposomal Lactoferrin as Potential Preventative and Cure for COVID-19 |
| Prospective study of treatment with lactoferrin, vitamin C, and zinc, reporting recovery for all patients within 5 days. Depending on symptoms, lactoferrin nasal drops, mouth spray, or nebulization was also used. | ||
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.